← Back

Wire · opportunities

ANTITRUST NEWS: FTC touts Caremark settlement will drive down patient costs, increase ...

Published

16 July 2026

Topic

opportunities

Sectors

Digital Health

Geography

United States

Source

Read at vitallaw.com

Verified

Fusion42 · 16 July 2026 · Fusion42 review

The FTC settled with Caremark (CVS Health subsidiary), a major pharmacy benefit manager, requiring business practice changes including insulin price caps, increased transparency, and fair treatment of community pharmacies. The settlement locks in $8.5 billion in consumer savings over 10 years with potential additional $4.5 billion from point-of-sale rebates.

This Wire brief sits within Fusion42's coverage of Digital Health.

◆ The Wire takeaway

If you're building community pharmacy tech or supply chain software, Caremark just lost the ability to use rebates and pricing opacity as a weapon against you. Independent pharmacies now have 10 years of regulatory cover to build a viable alternative to the PBM margin squeeze.

Coverage

1 source · 16 Jul 2026

Related on Wire

Topics

Digital Healthpbm-reformpharmacy-competitiondrug-pricinginsulin-accessftc-enforcement